12 results about "Measles" patented technology

The invention belongs to but not limited to the technical field of human and animal health diagnostics, and discloses a binding molecule for acute infection diagnosis adapted to a point-of-care (POC) scene, an acute infection diagnosis system and a kit. The binding molecule is an antibody, a nano antibody or an aptamer (preferably not combined with IgM) which is specifically combined with a J chain of dIgA, steric hindrance and conformation rearrangement are avoided by combining the J chain, and the flexibility of a compound is kept so as to efficiently combine with an antigen; the diagnostic system and the kit are adapted to POC scenarios (such as lateral flow test strips). The problems that POC deployment is difficult, RAT sensitivity is low and dIgA detection efficiency of CSC is low in existing NAT are solved, and the kit has the advantages of being low in cost, high in specificity and good in stability, can be used for rapid diagnosis of multiple acute infections such as measles and syphilis, fills up related technical gaps and has high commercial value.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The invention provides a method for rescuing a novel measles recombinant coronavirus. The pGEM3Zf (+)-T7RNAP plasmid constructed by the invention can be subjected to in-vitro reverse transcription processing to obtain T7RNA polymerase mRNA (messenger Ribonucleic Acid). The method comprises the following steps: by taking an MRC-5 cell as a cell matrix, co-transfecting the MRC-5 cell by using a pT7-MVEZ-COV2S.B.1.617.2 plasmid constructed by the invention and a helper plasmid in a physical electric shock manner, and simultaneously transfecting T7RNA polymerase mRNA (messenger ribonucleic acid). T7RNA polymerase mRNA translates and expresses T7RNA polymerase in an MRC-5 cell, the T7RNA polymerase further drives a T7 promoter, transcription of a full-length plasmid containing all genetic information of the virus and expression of N, P and L genes are started, virus packaging and proliferation are completed in a host cell, and the paramyxovirus with infection activity is obtained.

The present invention relates to recombinant measles viruses expressing Lassa virus polypeptides, in particular immunogenic LASV particles expressed by measles viruses and / or virus-like particles (VLPs) containing Lassa virus proteins. These particles are recombinant infectious particles capable of replicating in a host after administration. The present invention provides means for generating these recombinant infectious particles, in particular nucleic acid constructs, vectors, cells and rescue systems. The present invention also relates to the use of these recombinant infectious particles, in particular in the form of a composition, more specifically in a vaccine formulation, for the treatment or prevention of Lassa virus infection.

The invention provides a capturing probe group and a kit for a measles virus full-length genome and a sequencing method of the measles virus full-length genome, and belongs to the technical field of virus detection. The invention relates to an inactive probe group of a measles virus full-length genome. The inactive probe group comprises probes with nucleotide sequences as shown in SEQ ID NO: 1-SEQ ID NO: 742. The capturing probe group and next-generation sequencing are combined to obtain a measles full-length genome sequence. Compared with a primer or a probe used in a sequencing method in the prior art, the single probe in the probe group is short and high in specificity, the same site is designed by using the imbricate probe, all variations of the site are covered, and when a virus sequence is captured, the probe group has the characteristics of high sensitivity, high coverage rate and high flux.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes encoding Epstein-Barr Virus (EBV) proteins, e.g., gp350, gH, gL, and gp42, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding EBV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to EBV in subjects.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes for herpes simplex virus (HSV) proteins, e.g., glycoprotein B, glycoprotein C, glycoprotein D, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding HSV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to HSV in subjects.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3)), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in a subject.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition, a traditional Chinese medicine preparation and a preparation method and application thereof. According to the preparation method, the traditional Chinese medicine composition and the preparation thereof provided by the invention, the extraction transfer rate of active effective components of the prescription medicines is improved; the traditional Chinese medicine composition can be used for reducing body temperature, resisting viruses, and / or treating cold and cough, upper respiratory tract infection, acute and chronic tracheal and bronchitis, pneumonia, bronchial asthma, measles combined pneumonia, children pertussis and / or pungent and cool catharsis, clearing lung and relieving asthma, and relieving cough and reducing phlegm.

1. The name of the design product: medicine packaging bag (Xiao'er Majiang granules). 2. The use of the design product: the medicine packaging bag is used for packaging (Xiao'er Majiang granules). 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view. 5. The design product is a thin product, so the left view is omitted; the design product is a thin product, so the right view is omitted; the design product is a thin product, so the top view is omitted; the design product is a thin product, so the bottom view is omitted.